ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock

Informations projet

ZENEO

N° de convention de subvention: 876000

DOI

10.3030/876000

Projet clôturé

Date de signature de la CE 5 Juillet 2019

Date de début 1 Août 2019

Date de fin 30 Novembre 2019

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

CROSSJECT
France

Periodic Reporting for period 1 - ZENEO (ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock)

Période du rapport: 2019-08-01 au 2019-11-30

Résumé du contexte et des objectifs généraux du projet

Anaphylactic shock is a rare, severe and rapid onset allergic reaction that can be treated with the injection of Adrenaline, but if left untreated may cause death by asphyxia in 20 minutes. Adrenaline auto-injectors are needle-based pre-filled devices for self-injection into the muscle of the outer side of the thigh. User tests of some leading auto-injectors show a poor success rate after six weeks (42% or 43% depending on the auto-injectors), half of errors being that people do not wait long enough (above 3 seconds) while the needle injects inside the muscle.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

During the Feasibility Study period, Crossject finetuned the market approach and essential arguments, focusing on the market drivers and advantages versus current solutions and the cost to take ZENEO® Adrenaline to TRL9. A sales forecast for three years post-project was prepared based on market analysis.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Crossject has used a combination of cutting-edge technologies to develop ZENEO® in such a way that it is capable of injecting a tiny jet of Adrenaline through a patient’s skin by propelling it at very high pressure and speed. All in all ZENEO® has been developed to relieve fear of needles; eliminate all risks of injury; and perform a true intramuscular injection by non-healthcare professionals due to its quick, one-handed use, thus excluding any risk of contamination and pollution of needles disposal. Crossject aims to be a leader of emergency use drug –device pharmaceutical products to save lives simply.

image1.png